Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): A final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial

The SOLO2/ENGOT-Ov21 Investigators

doi:10.1097/OGX.0000000000000962

Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): A final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial

The SOLO2/ENGOT-Ov21 Investigators

Obstetrics & Gynecology

Research output: Contribution to journal › Comment/debate

3 Scopus citations

Original language	English
Pages (from-to)	535-536
Number of pages	2
Journal	Obstetrical and Gynecological Survey
Volume	76
Issue number	9
DOIs	https://doi.org/10.1097/OGX.0000000000000962
State	Published - 1 Sep 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1097/OGX.0000000000000962

Cite this

@article{a0f5231c90ec456ea42c343d50d21ebc,

title = "Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): A final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial",

author = "{The SOLO2/ENGOT-Ov21 Investigators} and Andr{\'e}s Poveda and Anne Floquet and Ledermann, {Jonathan A.} and Rebecca Asher and Penson, {Richard T.} and Oza, {Amit M.} and Jacob Korach and Tomasz Huzarski and Sandro Pignata and Michael Friedlander and Alessandra Baldoni and Park-Simon, {Tjoung Won} and Kenji Tamura and Sonke, {Gabe S.} and Alla Lisyanskaya and Kim, {Jae Hoon} and Filho, {Elias Abdo} and Tsveta Milenkova and Lowe, {Elizabeth S.} and Phil Rowe and Ignace Vergote and Eric Pujade-Lauraine",

year = "2021",

month = sep,

day = "1",

doi = "10.1097/OGX.0000000000000962",

language = "אנגלית",

volume = "76",

pages = "535--536",

journal = "Obstetrical and Gynecological Survey",

issn = "0029-7828",

publisher = "Lippincott Williams and Wilkins Ltd.",

number = "9",

}

The SOLO2/ENGOT-Ov21 Investigators 2021, 'Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): A final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial', Obstetrical and Gynecological Survey, vol. 76, no. 9, pp. 535-536. https://doi.org/10.1097/OGX.0000000000000962

Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): A final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. / The SOLO2/ENGOT-Ov21 Investigators.
In: Obstetrical and Gynecological Survey, Vol. 76, No. 9, 01.09.2021, p. 535-536.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21)

T2 - A final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial

AU - The SOLO2/ENGOT-Ov21 Investigators

AU - Poveda, Andrés

AU - Floquet, Anne

AU - Ledermann, Jonathan A.

AU - Asher, Rebecca

AU - Penson, Richard T.

AU - Oza, Amit M.

AU - Korach, Jacob

AU - Huzarski, Tomasz

AU - Pignata, Sandro

AU - Friedlander, Michael

AU - Baldoni, Alessandra

AU - Park-Simon, Tjoung Won

AU - Tamura, Kenji

AU - Sonke, Gabe S.

AU - Lisyanskaya, Alla

AU - Kim, Jae Hoon

AU - Filho, Elias Abdo

AU - Milenkova, Tsveta

AU - Lowe, Elizabeth S.

AU - Rowe, Phil

AU - Vergote, Ignace

AU - Pujade-Lauraine, Eric

PY - 2021/9/1

Y1 - 2021/9/1

UR - http://www.scopus.com/inward/record.url?scp=85117201236&partnerID=8YFLogxK

U2 - 10.1097/OGX.0000000000000962

DO - 10.1097/OGX.0000000000000962

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.comment???

AN - SCOPUS:85117201236

SN - 0029-7828

VL - 76

SP - 535

EP - 536

JO - Obstetrical and Gynecological Survey

JF - Obstetrical and Gynecological Survey

IS - 9

ER -

Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): A final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial

UN SDGs

Access to Document

Other files and links

Cite this